However, treatment options remain limited for the patients that lack mutations in the five most commonly mutated melanoma genes (BRAF, NRAS, KIT, GNAQ and GNA11) and the prognosis of such patients is particularly pool with a median overall survival of less than 1 year (7). This evidence concerns the gene NRAS and melanoma.